Bli medlem
Bli medlem

Du är här

2016-10-27

Minerva Neurosciences to Report Third Quarter 2016 Financial Results and Business Updates on November 3, 2016

Minerva Neurosciences, Inc.
Press release

Minerva Neurosciences to Report Third Quarter 2016 Financial Results and
Business Updates on November 3, 2016

Management to host conference call

WALTHAM, Mass., 2016-10-27 14:30 CEST (GLOBE NEWSWIRE) --
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical
company focused on the development of therapies to treat central nervous system
(CNS) disorders, today announced that it will release financial results and
business updates for the third quarter of 2016 on Thursday, November 3, 2016.
The Company will host a webcast and conference call that day at 8:30 a.m.
Eastern Time to discuss these results and updates.

The live call may be accessed by dialing (877) 312-5845 for domestic callers or
(765) 507-2618 for international callers and referring to conference ID number
90389179. A live webcast of the conference call will be available online in
the Investors and Media section of the Company’s website at
ir.minervaneurosciences.com. The archived webcast will be available on the
Company’s website beginning approximately two hours after the event for 30
days.

About Minerva Neurosciences:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of a portfolio of products to
treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, which
has completed a Phase IIb clinical trial for schizophrenia; MIN-117, which has
completed a Phase IIa clinical trial development for MDD; MIN-202
(JNJ-42847922), which has completed Phase IIa and Phase Ib clinical trials for
insomnia and MDD, respectively; and MIN-301, in pre-clinical development for
Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global
Market under the symbol “NERV.” For more information, please visit
www.minervaneurosciences.com.

Contact:

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.